Fig. 2From: A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumorsTroriluzole and riluzole concentrations (ng/mL) in human EDTA K2 plasma, average per dosing cohort taken before and 2 and 4 h after oral dosing at Week 2 (the beginning of troriluzole treatment), and pre-dose at Week 1 (before nivolumab) and Week 7 (after treatment with nivolumab)Back to article page